|MDACC Study No:||2011-0856 (clinicaltrials.gov NCT No: NCT01431209)|
|Title:||A Phase 2 Multicenter, investigator initiated study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma|
|Principal Investigator:||Yasuhiro Oki|
|Study Description:||The goal of this clinical research study is to learn if ruxolitinib phosphate |
(ruxolitinib) can help to control lymphoma. The safety of this drug will also
Ruxolitinib is designed to block the activity of proteins in the body (called
JAKs) that have been associated with cancer growth and survival. Blocking
these proteins may cause the cancer cells to die.